A Message from Chairman and CEO Alex Gorsky About Johnson & Johnson's Investigational COVID-19 Vaccine Candidate
Did you like reading this story? Click the heart to show your love.
A Message from Chairman and CEO Alex Gorsky About the Emergency Use Authorization of Johnson & Johnson's Janssen COVID-19 VaccineDid you like reading this message? Click the heart to show your love.
Johnson & Johnson Chairman and CEO Appears at the White House to Discuss the Company's Collaboration with Merck and Future Vaccine ProductionDid you like reading this story? Click the heart to show your love.
One year ago this week, Johnson & Johnson pledged that we would leverage all of our capabilities to fight an emerging threat, then being referred to as simply “the novel coronavirus.” Since then, we have focused our efforts on delivering a single-dose vaccine that would be a safe, effective and efficient solution for the largest number of people around the world.
I couldn’t be more proud—or grateful—to share that we have made a significant step towards reaching our ambitious goal.
Today, we shared positive topline Phase 3 clinical trial results for our single-dose investigational COVID-19 vaccine candidate. We will continue to work with health authorities around the world on regulatory applications.
Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic.ShareDid you like reading this message? Click the heart to show your love.
COVID-19 has touched the lives of every person on this planet and tested us as a society and as individuals. But Johnson & Johnson was built for times like these—and from day one, we have kept science, transparency and collaboration at the center of all our efforts to fight this deadly pandemic. Our work on an investigational COVID-19 vaccine will be an enduring point of pride for us for decades to come.
Doing our part to combat the greatest public health crisis in living memory has been a huge undertaking for our company. I owe a deep debt of gratitude to the incredible teams that made this milestone a reality, and to each and every one of my 135,000 colleagues for living into Our Credo values with great resilience and agility to ensure we keep meeting the healthcare needs of all who rely on Johnson & Johnson.
COVID-19 continues to inflict heartbreak and hardship, and there is still much that must be done to bring this pandemic to an end. But I am more optimistic than ever that these dark days are numbered.
I hope that our announcement today serves as a welcome reminder of the transformative power of science, the multiplying effect of collaboration and—most of all—the possibility of a better, healthier future.